Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice
Marta Pardo, Yuyan Cheng, Dmitry Velmeshev, Marco Magistri, Hagit Eldar-Finkelman, Ana Martinez, Mohammad A. Faghihi, Richard S. Jope, Eleonore Beurel
Marta Pardo, Yuyan Cheng, Dmitry Velmeshev, Marco Magistri, Hagit Eldar-Finkelman, Ana Martinez, Mohammad A. Faghihi, Richard S. Jope, Eleonore Beurel
View: Text | PDF
Research Article Neuroscience

Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice

  • Text
  • PDF
Abstract

Molecular mechanisms underlying learning and memory remain imprecisely understood, and restorative interventions are lacking. We report that intranasal administration of siRNAs can be used to identify targets important in cognitive processes and to improve genetically impaired learning and memory. In mice modeling the intellectual deficiency of Fragile X syndrome, intranasally administered siRNA targeting glycogen synthase kinase-3β (GSK3β), histone deacetylase-1 (HDAC1), HDAC2, or HDAC3 diminished cognitive impairments. In WT mice, intranasally administered brain-derived neurotrophic factor (BDNF) siRNA or HDAC4 siRNA impaired learning and memory, which was partially due to reduced insulin-like growth factor-2 (IGF2) levels because the BDNF siRNA– or HDAC4 siRNA–induced cognitive impairments were ameliorated by intranasal IGF2 administration. In Fmr1–/– mice, hippocampal IGF2 was deficient, and learning and memory impairments were ameliorated by IGF2 intranasal administration. Therefore intranasal siRNA administration is an effective means to identify mechanisms regulating cognition and to modulate therapeutic targets.

Authors

Marta Pardo, Yuyan Cheng, Dmitry Velmeshev, Marco Magistri, Hagit Eldar-Finkelman, Ana Martinez, Mohammad A. Faghihi, Richard S. Jope, Eleonore Beurel

×

Figure 9

Intranasal treatment with insulin-like growth factor-2 (IGF2) restores impaired cognition after intranasal brain-derived neurotrophic factor (BDNF) siRNA administration.

Options: View larger image (or click on image) Download as PowerPoint
Intranasal treatment with insulin-like growth factor-2 (IGF2) restores i...
We tested if intranasal administration of IGF2 altered the performance of BDNF siRNA–treated WT mice in novel object recognition and coordinate spatial processing to determine if deficient IGF2 contributed to impairments induced by knocking down BDNF. WT mice received BDNF siRNA (3 μg/mouse) 48 hours prior to behavioral testing. IGF2 (0.1 μg/mouse/day; gray bars) or vehicle (white bars) was administered 24 hours and 1 hour prior to behavioral testing. (A) BDNF siRNA–treated mice displayed a deficit in novel object recognition, displaying no difference in exploration of the novel and familiar objects (n = 9; t(10) = 0.92, n.s.) that was rescued by treatment with IGF2 and led to preferential exploration of the novel object (n = 8; t(14) = 7.67, *P < 0.01 compared with % time spent exploring familiar [F] object). (B) Discrimination index is shown for novel object recognition (t(15) = 4.29, *P < 0.01 compared with BDNF siRNA–treated mice). (C) BDNF siRNA–treated mice displayed impairments in coordinate spatial processing (n = 9) that was rescued by treatment with IGF2 (n = 8; t(15) = 2.59, *P < 0.05 compared with BDNF siRNA–treated mice). Values are means ± SEM. Each symbol represents the value from an individual mouse. Student’s t test was used to analyze each behavioral test.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts